XML 60 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1
Investments and Fair Value Measurements - Narrative (Details)
 3 Months Ended 12 Months Ended
Aug. 18, 2021
USD ($)
Jan. 02, 2020
USD ($)
Apr. 25, 2019
USD ($)
Nov. 01, 2018
USD ($)
$ / shares
Jan. 02, 2022
USD ($)
Jul. 04, 2021
USD ($)
Mar. 29, 2020
USD ($)
Dec. 29, 2019
USD ($)
Jan. 02, 2022
USD ($)
venture
Jan. 03, 2021
USD ($)
Dec. 29, 2019
USD ($)
Feb. 28, 2021
USD ($)
Jul. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Marketable equity securities         $ 107,000,000       $ 107,000,000 $ 376,000,000      
Strategic equity investments, without readily determinable fair values         40,000,000       40,000,000 314,000,000      
Gains on deconsolidation                 0 0 $ 54,000,000    
Gain (loss) on Helix contingent value right                 30,000,000 7,000,000 (1,000,000)    
(Gain) loss on derivative assets related to terminated acquisition                 (26,000,000) 25,000,000 0    
Measurement period adjustment                 (5,000,000)        
Change in fair value of contingent consideration liabilities                 4,000,000 0 0    
Business Combination, Contingent Consideration, Liability                          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Change in estimated fair value                 4,000,000        
Cash payments         (15,000,000)       15,000,000        
PacBio                          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Cash       $ 1,200,000,000                  
Share price (in dollars per share) | $ / shares       $ 8.00                  
Payment of contingent consideration             $ 132,000,000            
Equity or debt financing to be raised   $ 100,000,000                      
Derivative assets related to terminated acquisition               $ 10,000,000   40,000,000 10,000,000    
PacBio | Reverse Termination Fee                          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Payment of contingent consideration   $ 98,000,000                      
Period for contingent consideration to be repayable   2 years                      
PacBio | Continuation Advances                          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Payment of contingent consideration             34,000,000 18,000,000          
Period for contingent consideration to be repayable   2 years                      
Maximum amount payable to PacBio   $ 52,000,000                      
PacBio | Selling, general and administrative                          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
(Gain) loss on derivative assets related to terminated acquisition             $ 92,000,000 $ 8,000,000          
PacBio | Other Operating Income Expense                          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Unrealized gain (loss) on derivatives                   (25,000,000)      
GRAIL                          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Payments to acquire additional investments                   60,000,000      
SB Northstar LP                          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Maximum amount payable to PacBio                       $ 52,000,000  
Series of Individually Immaterial Business Acquisitions                          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Fair value of contingent consideration           $ 14,000,000              
Change in fair value of contingent consideration liabilities                 (1,000,000)        
GRAIL Inc                          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Cash $ 2,862,000,000                        
Measurement period adjustment         (5,000,000)                
Change in estimated fair value                 7,000,000        
Fair value of contingent consideration $ 757,000,000                        
Change in fair value of contingent consideration liabilities         5,000,000       3,000,000        
Helix Holdings I, LLC                          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Gains on deconsolidation     $ 39,000,000                    
Contingent value right     $ 30,000,000                    
Gain (loss) on Helix contingent value right                 30,000,000 7,000,000 (1,000,000)    
PacBio | SB Northstar LP                          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
(Gain) loss on derivative assets related to terminated acquisition                 $ (26,000,000)        
PacBio | SB Northstar LP | Convertible Senior Notes                          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Principal amount of notes outstanding                       $ 900,000,000  
Venture Capital Investment Fund (the Fund)                          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Number of venture capital investment funds | venture                 2        
Equity method investments         173,000,000       $ 173,000,000 104,000,000      
Unrealized gain on equity method investments                 55,000,000 20,000,000 9,000,000    
Venture Capital Investment Fund (the Fund), One                          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Commitment in new venture capital investment fund         100,000,000       100,000,000        
Remaining capital commitment         20,000,000       20,000,000        
Venture Capital Investment Fund (the Fund), Two                          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Commitment in new venture capital investment fund         150,000,000       150,000,000        
Remaining capital commitment         $ 118,000,000       118,000,000        
Investee                          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Revenue from transactions with strategic investees                 $ 74,000,000 62,000,000 $ 71,000,000    
Variable Interest Entity, Not Primary Beneficiary | GRAIL                          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Net assets                   $ 250,000,000      
Variable Interest Entity, Primary Beneficiary | Helix Holdings I, LLC                          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Absorbed Helix's losses percentage                     50.00%    
Variable Interest Entity, Primary Beneficiary | Helix Holdings I, LLC                          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Equity ownership interest percentage                         50.00%